THE WOODLANDS, Texas,
Nov. 3, 2017 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release
its third quarter 2017 financial results on Wednesday, November 8, 2017 before market opens.
Management will conduct a conference call and live webcast at
8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial
results and to provide a business update.
Dial-in Information
U.S. Dial-in Number: (888)
645-5785
International Dial-in Number: (970) 300-1531
Conference ID: 9047069
Replay Information
U.S. Dial-in Number: (855)
859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 9047069
The dial-in replay will be available for 7 days following the
call. An audio webcast will be available online in the investor
relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and future
operating results, discovery, development and commercialization of
products, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information.
All forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to meet its capital requirements, successfully
commercialize XERMELO (telotristat ethyl), successfully conduct
preclinical and clinical development and obtain necessary
regulatory approvals of sotagliflozin, LX2761, LX9211 and its other
potential drug candidates on its anticipated timelines, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2016, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
View original
content:http://www.prnewswire.com/news-releases/lexicon-pharmaceuticals-to-host-third-quarter-2017-financial-results-conference-call-and-webcast-on-november-8-2017-300549141.html
SOURCE Lexicon Pharmaceuticals, Inc.